🧬 Immunology Updates: Major moves in myasthenia gravis, Crohn’s, psoriasis, psoriatic arthritis, and more!
From breakthrough FDA approvals to billion-dollar partnerships, this week’s highlights reveal how leading players are reshaping the immunology landscape.
🔬 This week’s key stories include:
💉 AstraZeneca’s gefurulimab improves myasthenia gravis symptoms at 26 weeks. The self-injectable C5 inhibitor may replace infused options like Soliris.
✅ Guselkumab (Tremfya®) is FDA-approved for Crohn’s, outperforming ustekinumab in head-to-head IL-23 trials.
🧬 Johnson & Johnson aims to update TREMFYA®’s label in psoriatic arthritis with data showing strong joint protection via dual IL-23 and CD64 targeting.
🦵 Sun Pharma’s Ilumya hits key endpoints in psoriatic arthritis—effective in both biologic-naïve and experienced patients, with no new safety signals.
📆 Sotyktu (Bristol Myers Squibb) under FDA review for psoriatic arthritis, with a decision expected by March 6, 2026. Trials show sustained joint relief.
💊 J&J’s icotrokinra, a once-daily oral IL-23 blocker for plaque psoriasis, outperformed Sotyktu across four Phase 3 trials.
🤝 GSK partners with Hengrui to access 12 immunology assets—including a dual PDE3/4 inhibitor for COPD—in a deal worth up to $12 billion.
📢 Stay Ahead in Immunology Research!
✅ Like, share, and subscribe for weekly updates on immunology and autoimmune diseases
#Immunology #AutoimmuneDiseases #PsoriaticArthritis #CrohnsDisease #Biologics #MyastheniaGravis #PlaquePsoriasis #LucidQuest #ClinicalTrials #FDAupdates #MedicalNews #HealthcareInnovation